Thromboembolic events in the hemodialysis setting: understanding risk profiles and cumulative incidences to inform clinical trial design.
Karaboyas, Angelo Zhao, Junhui Tanko, Laszlo B Joergensen, Kristian Tore Pap, Akos F Dasgupta, Indranil Nangaku, Masaomi Jadoul, Michel Pecoits-Filho, Roberto
Karaboyas, Angelo
Zhao, Junhui
Tanko, Laszlo B
Joergensen, Kristian Tore
Pap, Akos F
Dasgupta, Indranil
Nangaku, Masaomi
Jadoul, Michel
Pecoits-Filho, Roberto
Abstract
Background: People with kidney failure have a high risk of cardiovascular morbidity/death, including thromboembolic events. Factor XIa inhibitors are a new class of anticoagulants in development that may offer antithrombotic benefits with a lower risk of incremental bleeding events than traditional therapies. We investigated major adverse vascular events (MAVEs), a relevant composite outcome for testing novel antithrombotic agents, in a large cohort of patients on hemodialysis, to better understand the key requirements to adequately design a phase 3 trial.
Methods and results: We included 25 211 patients on hemodialysis for >90 days in phases 4 to 7 (2009-2021) of the DOPPS (Dialysis Outcomes and Practice Patterns Study). Atherosclerotic cardiovascular disease (ASCVD) was defined as history/presence of coronary, peripheral, or cerebrovascular disease. We estimated MAVE rates and cumulative incidence, overall and by ASCVD. Over half (52%) of the cohort met the ASCVD criteria. The MAVE hospitalization/death composite rate (per 100 patient-years) was 6.0 in the overall cohort and 8.7 in the ASCVD subset. Three-year cumulative incidence of MAVE was 13% in the overall cohort and 18% in the ASCVD subset. The estimated sample size to be randomized in a hypothetical trial in the ASCVD population was ≈7000 patients.
Conclusions: Even in the enriched ASCVD group, the observed MAVE incidence combined with a high competing risk, regulatory requirements (α=0.01), and limited recruitment pool makes feasibility of a potential randomized trial targeting MAVE reduction challenging. These results highlight key considerations and challenges for developers of novel therapies targeting systemic thromboembolic events in patients on hemodialysis.
MIDER Authors
Citations
Altmetric:
Date
2024-12-24
Type
Article
Other
Other
Subject
Vascular diseases, Cardiology, Nephrology/Renal medicine
Collections
Citation
Karaboyas A, Zhao J, Tanko LB, Joergensen KT, Pap AF, Dasgupta I, Nangaku M, Jadoul M, Pecoits-Filho R. Thromboembolic Events in the Hemodialysis Setting: Understanding Risk Profiles and Cumulative Incidences to Inform Clinical Trial Design. J Am Heart Assoc. 2025 Jan 7;14(1):e033983. doi: 10.1161/JAHA.124.033983.
Journal / Source Title
Journal of the American Heart Association
DOI
10.1161/JAHA.124.033983
PMID
39719420
Publisher
Wiley-Blackwell
Publisher’s URL
http://jaha.ahajournals.org/